BR112016024756A2 - regimes de dosagem de nitisinona para o tratamento da alcaptonúria - Google Patents

regimes de dosagem de nitisinona para o tratamento da alcaptonúria

Info

Publication number
BR112016024756A2
BR112016024756A2 BR112016024756A BR112016024756A BR112016024756A2 BR 112016024756 A2 BR112016024756 A2 BR 112016024756A2 BR 112016024756 A BR112016024756 A BR 112016024756A BR 112016024756 A BR112016024756 A BR 112016024756A BR 112016024756 A2 BR112016024756 A2 BR 112016024756A2
Authority
BR
Brazil
Prior art keywords
nitisinone
alcaptonuria
treatment
dosing regimens
administered
Prior art date
Application number
BR112016024756A
Other languages
English (en)
Portuguese (pt)
Inventor
Olsson Birgitta
Original Assignee
Swedish Orphan Biovitrum Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Int Ab filed Critical Swedish Orphan Biovitrum Int Ab
Publication of BR112016024756A2 publication Critical patent/BR112016024756A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112016024756A 2014-04-30 2015-04-29 regimes de dosagem de nitisinona para o tratamento da alcaptonúria BR112016024756A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450521 2014-04-30
PCT/EP2015/059352 WO2015165972A1 (en) 2014-04-30 2015-04-29 Nitisinone dosing regimens for the treatment of alkaptonuria

Publications (1)

Publication Number Publication Date
BR112016024756A2 true BR112016024756A2 (pt) 2017-08-15

Family

ID=53175441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024756A BR112016024756A2 (pt) 2014-04-30 2015-04-29 regimes de dosagem de nitisinona para o tratamento da alcaptonúria

Country Status (11)

Country Link
US (1) US20170049716A1 (enExample)
EP (1) EP3137066A1 (enExample)
JP (1) JP2017514820A (enExample)
AU (1) AU2015254669A1 (enExample)
BR (1) BR112016024756A2 (enExample)
CA (1) CA2947062A1 (enExample)
IL (1) IL248506A0 (enExample)
MA (1) MA39918A (enExample)
SG (1) SG11201608957VA (enExample)
TN (1) TN2016000479A1 (enExample)
WO (1) WO2015165972A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838039C (en) * 2011-06-23 2017-10-24 Swedish Orphan Biovitrum International Ab Liquid pharmaceutical composition comprising nitisinone

Also Published As

Publication number Publication date
JP2017514820A (ja) 2017-06-08
SG11201608957VA (en) 2016-11-29
MA39918A (fr) 2017-03-08
EP3137066A1 (en) 2017-03-08
WO2015165972A1 (en) 2015-11-05
IL248506A0 (en) 2016-12-29
AU2015254669A1 (en) 2016-12-15
US20170049716A1 (en) 2017-02-23
CA2947062A1 (en) 2015-11-05
TN2016000479A1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
EP3222278C0 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
BR112016027435A2 (pt) formulação inovadora de meloxicam
BR112016018685A2 (pt) regime de dosagem com composto de fgf-18
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2018000872A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
CL2018003707A1 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo.
BR112016024756A2 (pt) regimes de dosagem de nitisinona para o tratamento da alcaptonúria

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2564 DE 2020-02-27

B350 Update of information on the portal [chapter 15.35 patent gazette]